1. Home
  2. SNTI vs BDL Comparison

SNTI vs BDL Comparison

Compare SNTI & BDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$1.23

Market Cap

53.6M

Sector

Health Care

ML Signal

HOLD

Logo Flanigan's Enterprises Inc.

BDL

Flanigan's Enterprises Inc.

N/A

Current Price

$29.48

Market Cap

53.2M

ML Signal

N/A

Company Overview

Basic Information
Metric
SNTI
BDL
Founded
2016
1959
Country
United States
United States
Employees
N/A
1990
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
53.6M
53.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SNTI
BDL
Price
$1.23
$29.48
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
4.1M
616.0
Earning Date
11-13-2025
12-26-2025
Dividend Yield
N/A
1.92%
EPS Growth
N/A
41.91
EPS
N/A
2.32
Revenue
N/A
$201,851,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$150.00
N/A
P/E Ratio
N/A
$12.31
Revenue Growth
N/A
8.84
52 Week Low
$1.26
$22.61
52 Week High
$5.96
$35.98

Technical Indicators

Market Signals
Indicator
SNTI
BDL
Relative Strength Index (RSI) 33.44 45.20
Support Level $1.34 $28.61
Resistance Level $2.88 $30.01
Average True Range (ATR) 0.24 0.23
MACD -0.10 -0.19
Stochastic Oscillator 0.62 36.94

Price Performance

Historical Comparison
SNTI
BDL

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

About BDL Flanigan's Enterprises Inc.

Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.

Share on Social Networks: